
STANDARD OPERATIONAL PROCEDURE (SOP) AUDITOR AND MONITOR VISITS

Purpose

The purpose of this standard operational procedure is to outline and enforce a standardized process for clinical trial monitor visits within the Investigational Drug Service (IDS) at University of Utah Health (UUH).

Definitions

- A. **Auditor or Monitor:** an individual who observes each trial site to ensure that the standardized operation procedures for the trial are being followed, reporting and managing any deviations from the investigation plan as they occur. An auditor/monitor may work directly with the sponsor company of a clinical trial, as an independent freelancer or for a contract research organization. Auditors/monitors may also do the following functions related to clinical research studies; ensure compliance with the clinical trial protocol, check clinical site activities, make on-site visits, review case report forms and communicate with clinical research coordinators.
- B. **Investigational drug:** A new drug or biological drug that is used in a clinical investigation. The term also includes a biological product that is used in vitro for diagnostic purposes. The terms "investigational drug" and "investigational new drug" are deemed to be synonymous for purposes of this part. Any drug which has not received FDA approval for use in humans. Also refers to any drug, which is FDA approved and is being used under protocol for human research, possibly outside of FDA approved labeling.
- C. **Investigational drug service:** A function of the Department of Pharmacy and provides support to ensure the safety and efficiency of trials at University of Utah Health that use investigational product(s)/investigational drug(s). Pharmacy personnel that perform investigational drug accountability at UUH satellite locations approved for conducting research protocols are considered an extension of the IDS.
- D. **Investigational product (IP):** A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use.
- E. **Vestigo®:** A 21 CFR Part 11 compliant electronic accountability software application designed specifically for investigational pharmacy use and utilized by University of Utah Health IDS. Refer to www.mccreadiegroupp.com/vestigo/ for additional information.

Description

A. Scheduling a visit for an audit

1. Auditor visits are to be scheduled by either the monitor or the study coordinator by using the IDS auditor scheduling webpage. The webpage collects the information needed to schedule the auditor prior to their visit and notifies IDS pharmacy personnel once the appointment has been scheduled by the auditor. The monitor is also responsible for notifying the research team of their intended visit to the IDS pharmacy.
2. It is the responsibility of the auditor or the research coordinator to schedule an auditor visit using the IDS auditor scheduling webpage. Auditor visits must be scheduled a minimum of 8 weeks in advance. Shorter notice may be allowed if approved by the IDS manager prior to scheduling. However, auditing space and resources are limited within IDS and shorter notice may not be feasible.
3. Visits are to be limited to a maximum of 2 business days, however, visits can be extended if the IDS can accommodate, with prior approval at time of scheduling.
4. Frequency and number of auditor visits per study is specific to each protocol (no defined maximum per year per the IDS).
5. Visits must be completed during regular IDS business hours
6. Only unblinded auditors are allowed to schedule visits with the IDS
7. Auditor visits may need to be scheduled in an off-site location to accommodate the time and space needed by the auditor in conjunction with other IDS activities; the IDS will coordinate this with the research team to ensure that research documents are kept in the appropriate chain of custody at all times during the audit visit.

B. Scheduling a Monitor Visit

1. Monitor visits are to be scheduled by either the monitor or the study coordinator by using the IDS auditor scheduling webpage. The webpage collects the information needed to schedule the monitor prior to their visit and notifies IDS pharmacy personnel once the appointment has been scheduled by the auditor. The monitor is also responsible for notifying the research team of their intended visit to the IDS pharmacy.
2. It is the responsibility of the monitor or the research coordinator to schedule a monitor visit using the IDS monitor scheduling webpage. Monitor visits must be scheduled a minimum of 4 weeks in advance. Shorter notice may be allowed if approved by the IDS manager prior to scheduling. However, monitoring space and resources are limited within IDS and shorter notice may not be feasible.
3. Visits are to be limited to a maximum of 1 hour, however, visits can be extended if the IDS can accommodate, with prior approval at time of scheduling.
4. The IDS can accommodate no more than 2 monitors during any given time frame, and no more than 8 hours of monitor visits per business day.
5. Frequency and number of monitor visits per study is specific to each protocol (no defined maximum per year per the IDS).
6. Visits must be completed during regular IDS business hours
7. Only unblinded monitors are allowed to schedule visits with the IDS

C. Preparation for Monitor Visit completed by the IDS

1. After a monitor visit has been confirmed using the IDS monitor scheduling webpage, IDS personnel to send standardized email to monitor including the monitor SOP and their Vestigo® access information.
2. Confirm that the regulatory study binder is complete and up-to-date.

3. Address and resolve any outstanding issues or data queries from prior monitoring visits.
 4. Provide Vestigo™ access day of scheduled visit.
- D. Monitor Expectations
1. Upon arrival to the IDS monitors will fill out and sign the Monitoring Visit Log.
 2. Computer access will be provided by the site, however, the monitor should come prepared with his or her laptop as needed.
 3. All monitors will utilize and document within Vestigo® to perform drug returns/destruction, and perform all accountability. No additional drug accountability forms or documents provided by the monitor will be used for drug accountability.
 4. Monitors must mark “returns” to be destroyed or to be sent back to the sponsor during the visit within Vestigo®. No additional drug accountability forms or documents provided by the monitor will be used for drug accountability.
 - a. It is the responsibility of the monitor to send a packing box to the IDS pharmacy prior to the visit, provide a shipping label, count inventory and package the return before the end of the visit.
 5. Monitors will provide a summary of their review and findings at the conclusion of the monitoring visit within Vestigo®. Any additional reviews that are provided post-monitor visit will be filed electronically within Vestigo®.
- E. Access to Study Information
1. Copies of study information may be provided to monitors in the following ways:
 - a. Physical copies of information from a physical pharmacy binder may be made only on the designated Monitor Printer.
 - i. There will be no scanning of documents done by monitors of information from a physical pharmacy binder
 - b. Monitors may generate accountability logs (or any other electronic documents made available to them in Vestigo®) and save them to the IDS desktop or secured laptop, and send to sponsor email.
 - i. After the conclusion of a monitor visit, accountability logs are ONLY available via email request. Printed accountability logs will be provided with an additional charge of special monitor fees to the study.
 - ii. The monitor must not send accountability records via personal email in any circumstance due to noncompliance with HIPPA.
 - iii. Research records must only be sent to a sponsor email address. It is the responsibility of the monitor to ensure the correct email address is being used. If an inappropriate email is used for sending research documents from Vestigo® then future monitoring visits may be revoked or refused.
 - c. Temperature monitoring logs will provide the monthly minimum/maximum temperatures and are ONLY available only via email after the conclusion of the monitor visit. Printed temperature monitoring logs will be provided with an additional charge of special monitor fees to the study.
 - d. All study documents and materials provided to the auditor/ monitor for review must be secured at all times with pharmacy personnel or a member of the research team present (auditors or monitors may not be left alone with research documents).
- F. Viewing Study Drug
1. For IP stored at ambient temperature, the monitor is permitted to view all study drug for the entire duration of the visit.

2. For IP stored in either a refrigerator or freezer, the IP it can only be removed from the storage area by IDS personnel. This IP may be viewed by the monitor for no more than 5 minutes to maintain product temperature and integrity.
 3. Current inventory on-hand can also be accounted for within Vestigo® without direct visualization per monitor digression.
- G. Monitor/Audit Visit Follow-Up
1. All communication between monitor and IDS will be done through Vestigo™ for items to be destroyed or returned.
 2. All communication between monitor and IDS will be done through email for any additional document procurement requested by the monitor post-monitor visit
 3. Communicate to the project pharmacist and IDS manager any issues that were discussed during the monitor visit.
 - a. Ensure any issues or follow-up discussed during the visit are followed up on and/or completed that day or passed along to another technician/pharmacist.
 4. Any potential issues identified at a monitoring visit or audit (including temperature excursions) should be provided to the PI, primary CRC, and the associated program manager.
- H. Technician Responsibilities Related to Monitor/Audit Visit
1. Prepare for monitor/audit visit (see above).
 2. Facilitate monitor visit.
 - a. Perform IDS pharmacy tour at first monitor visit and upon request.
 - b. Escort the monitor throughout the IDS pharmacy when needed (to view IP when stored in fridge or freezer, etc.).
- I. Pharmacist Responsibilities Related to Monitor/Audit Visit
1. Mitigate any issues during the monitor/audit visit as identified by technician.
 2. Follow up on any outstanding issues prior to and after the monitoring/auditing visit as identified by technician.
- J. Remote Monitoring
1. The IDS at UUH does not support remote monitoring for research protocols.
 2. If an extenuating circumstance arises, remote monitoring may be discussed with the IDS manger prior to approval.
 - a. The need for remote monitoring must be identified prior to the site initiation visit.
 - b. If remote monitor is arranged, an additional fee will be charged outside of what was provided in the IDS pharmacy estimate.

©2018 Department of Pharmacy Services, University of Utah Health, Salt Lake City, Utah. For more information, contact the Investigational Drug Service at 801-585-0272 or Investigational.Pharmacy@hci.utah.edu.

This information is provided through the support of University of Utah Health solely as a service to its affiliate hospital. Affiliate shall not disclose this information to any third party, or use this information for any purpose, other than Affiliate's own internal use. Users of this information are advised that decisions regarding the use of this information are complex and that in using this information each user must exercise his or her own independent professional judgment. University of Utah assumes no liability whatsoever for affiliate's use or reliance on this information, or otherwise in connection with this information.